Fig. 1

CD32b is homogeneously expressed at high level on primary CLL cells, but not significantly expressed on non-B hematopoietic cells. a Expression (% positive) of CD32 (n = 41), CD19 (n = 41), CD20 (n = 33), CD22 (n = 29), CD23 (n = 29), ROR1 (n = 22) and FcμR (n = 22) in CLL samples (from CLL patients in Additional file 1: Table S1). b Evaluation for site density of CD32 and other antigens in CLL patients (sample size was the same as a) using Quantibrite-PE beads. c Transcriptional profile of Fcgr2a, Fcgr2b and Fcgr2c from 2 CLL samples and Raji cell line by RNA sequencing. d Flow cytometric analysis of surface expression of CD32, CD32b and CD19 in 7 CLL patients. e Expression (% positive) of CD32, CD32b and CD19 in CLL patients (n = 7). f Site density comparison among CD32b, CD32 and CD19 in CLL patients (n = 7). Data in e–f belong to Pt 42–48, and the expression of CD32 and CD19 on samples from Pt 42–48 is not included in a–b. h Flow cytometric analysis of surface expression of CD32 on peripheral blood cells and HSPCs (CD34⁺ CD38⁻ HSCs and CD34⁺ CD38⁺ HPCs) from a healthy donor. i Flow cytometric analysis of CD32b expression on normal peripheral blood cells and HSPCs from a healthy donor. FPKM: expected number of Fragments Per Kilobase of transcript sequence per Millions base pairs sequenced. HSC, hematopoietic stem cell; HPC, hematopoietic progenitor cell; NK, natural killer; DC, dendritic cells. Data were representative of two independent experiments. Unpaired two-tailed Student's t test was used for statistical analyses in a, b; paired two-tailed Student's t test was used in e and f (*P < 0.05, **P < 0.01, ***P < 0.001)